Calabrese, Edward JNascarella, Marc A2024-04-262014-07-162010-03-01https://hdl.handle.net/20.500.14394/20586Enhanced drug (GDC 0449) resistance in a mouse model for human medulloblastoma is shown in the present paper to act via an hormetic response. This has significant implications, imposing constraints on the quantitative features of the dose response of the chemotherapeutic agent, affecting optimal study design, mechanism assessment strategy, potential for tumor rebound, patient relapse and disease outcome.hormesisbiphasicGDC 0449medulloblastomatumor relapsehedgehog pathwayarticle